Last Patient Treated in CARES10 Trial for Primary Immunodeficiency (PI)
[Source: pixabay.com]

Last Patient Treated in CARES10 Trial for Primary Immunodeficiency (PI)

According to a recent press release, biopharmaceutical company Kedrion Biopharma ("Kedrion") achieved an important milestone in its Phase 3 CARES10 trial: the last treated patient. During the CARES10 trial, researchers evaluated…

Continue Reading Last Patient Treated in CARES10 Trial for Primary Immunodeficiency (PI)

UK Moves to Make Whole Genome Sequencing Standard in the NHS, Improving Diagnosis for Rare Disease Patients

A recent study has demonstrated that through standardizing the whole genome sequencing process and making it routine for patients, we can improve rare disease diagnosis across the board. Earlier diagnosis…

Continue Reading UK Moves to Make Whole Genome Sequencing Standard in the NHS, Improving Diagnosis for Rare Disease Patients
New Method of Infusion for Primary Immunodeficiency Could Improve Patients; Quality of Life
source: pixabay.com

New Method of Infusion for Primary Immunodeficiency Could Improve Patients; Quality of Life

A New Study A new study, conducted by CLS Behring, has found that a new method of administration for Hizentra as a treatment for primary immunodeficiency (PI), could improve quality…

Continue Reading New Method of Infusion for Primary Immunodeficiency Could Improve Patients; Quality of Life
What if the World Always Thought of the Immunocompromised as They are Right Now?
source: pixabay.com

What if the World Always Thought of the Immunocompromised as They are Right Now?

If the world were as careful in everyday life Perhaps I’d be sick less, I’d feel much less strife It's the small precautions, like washing your hands That for me…

Continue Reading What if the World Always Thought of the Immunocompromised as They are Right Now?
ICYMI: Privigen Granted Orphan Drug Designation For Treatment of Systemic Scleroderma
source: pixabay.com

ICYMI: Privigen Granted Orphan Drug Designation For Treatment of Systemic Scleroderma

CSL Behring has recently received the Orphan Drug designation for Privigen for the treatment of systemic scleroderma. Privigen has also been granted the Fast Track designation. This therapy has been…

Continue Reading ICYMI: Privigen Granted Orphan Drug Designation For Treatment of Systemic Scleroderma
ADMA Biologics Earns BioNJ 2020 Innovator Award for Primary Immunodeficiency Treatment
source: pixabay.com

ADMA Biologics Earns BioNJ 2020 Innovator Award for Primary Immunodeficiency Treatment

According to a story from gurufocus.com, the biopharmaceutical company ADMA Biologics, Inc., has earned the 2020 BioNJ Innovator Award. This award was given as acknowledgement of the company's successful development…

Continue Reading ADMA Biologics Earns BioNJ 2020 Innovator Award for Primary Immunodeficiency Treatment
Orphan Drug Designation Provided to a Treatment for Chronic Inflammatory Demyelinating Polyneuropathy
source: pixabay.com

Orphan Drug Designation Provided to a Treatment for Chronic Inflammatory Demyelinating Polyneuropathy

The FDA has just provided Orphan Drug Designation to Hizentra for the treatment of adults diagnosed with chronic inflammatory demyelinating polyneuropathy (CIPD). This is a maintenance therapy which works to…

Continue Reading Orphan Drug Designation Provided to a Treatment for Chronic Inflammatory Demyelinating Polyneuropathy

Breakthrough Therapy Designation Given to Investigative WHIM Syndrome Treatment

WHIM Syndrome WHIM syndrome is a form of primary immunodeficiency. It is caused by a mutation in the CXCR4 gene. WHIM stands for Warts, Hypogammaglobulinemia, Infections, and Myelokathexis. Throughout their…

Continue Reading Breakthrough Therapy Designation Given to Investigative WHIM Syndrome Treatment

PID Patients Could Receive More Personalized Treatment Thanks to New Study

A New Study A recent study published in Nature Immunology and conducted by researchers at the University of Basel has produced influential results regarding primary immunodeficiency disorders (PID). These rare disorders…

Continue Reading PID Patients Could Receive More Personalized Treatment Thanks to New Study
Two Best Friends With Primary Immunodeficiency Meet for the First Time in Cape Town, South Africa
Olichel / Pixabay

Two Best Friends With Primary Immunodeficiency Meet for the First Time in Cape Town, South Africa

According to a story from Cape Town Etc, two girls in South Africa were living with the same rare disease: primary immunodeficiency (PI), a group of rare conditions in which…

Continue Reading Two Best Friends With Primary Immunodeficiency Meet for the First Time in Cape Town, South Africa
Specialty Pharmacists Play Important Role in Treatment of Primary Immunodeficiency Patients
qimono / Pixabay

Specialty Pharmacists Play Important Role in Treatment of Primary Immunodeficiency Patients

A recent publication from Specialty Pharmacy Times noted that the rapidly-growing number of available human immunoglobulin treatments for primary immunodeficiency disorders could pose challenges for specialty pharmacists when treating patients.…

Continue Reading Specialty Pharmacists Play Important Role in Treatment of Primary Immunodeficiency Patients

Enrollment Opens for Phase 3 Study of Intravenous Immunoglobulin in Primary Immunodeficiency Patients

According to a publication from BioSpace, New Jersey-based Kedrion Biopharma recently announced the enrollment of the first participant in their CARES10 study. CARES10 is a phase 3 study of a…

Continue Reading Enrollment Opens for Phase 3 Study of Intravenous Immunoglobulin in Primary Immunodeficiency Patients
Primary Immunodeficiency in Children: Early Intervention is Important
RachelBostwick / Pixabay

Primary Immunodeficiency in Children: Early Intervention is Important

According to a story from The Indian Express, early treatment and diagnosis of primary immunodeficiencies makes management of this group of disease much simpler as a whole. In children, the…

Continue Reading Primary Immunodeficiency in Children: Early Intervention is Important
Possible Treatment for WHIM Syndrome Earns Orphan Drug Designation in the EU
Free-Photos / Pixabay

Possible Treatment for WHIM Syndrome Earns Orphan Drug Designation in the EU

According to a story from home.suddenlink.net, the biopharmaceutical company X4 Pharmaceuticals recently announced that the European Commission has granted Orphan Drug designation to the company's lead investigational drug candidate, mavorixafor.…

Continue Reading Possible Treatment for WHIM Syndrome Earns Orphan Drug Designation in the EU

A Plasma Shortage is Affecting Common Variable Immune Deficiency Patient’s Access to Treatment

Heather White Heather White is a 41-year-old woman who was diagnosed with common variable immune deficiency (CVID) back in 2004 after fighting frequent bouts of pneumonia. Doctors believe that she…

Continue Reading A Plasma Shortage is Affecting Common Variable Immune Deficiency Patient’s Access to Treatment
Teenage Girl Walks Again After Finally Getting Diagnosed With Complement C1q Deficiency and Bone Marrow Transplant
source: pixabay.com

Teenage Girl Walks Again After Finally Getting Diagnosed With Complement C1q Deficiency and Bone Marrow Transplant

  A young girl in Mauritius, an island in the Indian Ocean, has recently been given a second chance at a normal life after receiving a rare disease diagnosis and…

Continue Reading Teenage Girl Walks Again After Finally Getting Diagnosed With Complement C1q Deficiency and Bone Marrow Transplant

Vogmask Offers a Stylish Face Mask for Those Living with Immunodeficiencies

Vogmask is a San Francisco, California based company founded in 2011. They create stylish facial masks to protect wearers from inhalation of particulate and allergens. These types of masks can…

Continue Reading Vogmask Offers a Stylish Face Mask for Those Living with Immunodeficiencies

X4 Pharmaceuticals Reports Positive Phase 2 Results for WHIM Syndrome Drug

According to an article published by Biospace, X4 Pharmaceuticals, based in Cambridge, Massachusetts, has recently announced successful phase two results in clinical trials for their experimental drug X4P-001. The drug…

Continue Reading X4 Pharmaceuticals Reports Positive Phase 2 Results for WHIM Syndrome Drug